Demystifying Medicine Video



Idiopathic pulmonary fibrosis (IPF) is a disorder characterized by chronic and progressive scarring of lung tissue. The cause of this disease is currently unknown. However, it can significantly impair one’s quality of life as patients often experience difficulty breathing. The seriousness of this disease makes finding effective treatment of paramount importance. Current pharmacological interventions are riddled with side-effects. Several clinical trials are underway in hopes of finding an effective therapy with little to no side-effects. One of the drugs showing promise as a potential therapeutic for IPF is GB0139 (formerly TD139). Here, we delve deeper into the mechanism by which GB0139 functions and its current status within clinical trials, providing hope for individuals who have been diagnosed with IPF.

GB0139 (formerly TD139) - Specific Articles:
Resources
Hamilton Pulmonary Fibrosis Support

Group Contact: Stephen Binch stephen@cpff.ca 289-456-7223
Meeting Location: Fortino's Community Room, 1579 Main St West Hamilton, ON L8S 1E6

[Please complete our feedback form]




References
  • Canadian Lung Association. Idiopathic Pulmonary Fibrosis. The Lung Association, 2015.
  • Parmar, N. R., Mackinnon, A. C., Zetterberg, F., Ford, P., & Jenkins, R. G. (2019). Role of Galectin-3 in Idiopathic Pulmonary Fibrosis Development. In C62. FIBROBLAST BIOLOGY (pp. A5328-A5328). American Thoracic Society.
  • Loomis-King, H., Flaherty, K. R., & Moore, B. B. (2013). Pathogenesis, current treatments and future directions for idiopathic pulmonary fibrosis. Current opinion in pharmacology, 13(3), 377-385.
  • Xaubet, A., Marin-Arguedas, A., Lario, S., Ancochea, J., Morell, F., Ruiz-Manzano, J., ... & Campistol, J. M. (2003). Transforming growth factor-β1 gene polymorphisms are associated with disease progression in idiopathic pulmonary fibrosis. American journal of respiratory and critical care medicine, 168(4), 431-435.
  • Semedo, Daniela. Galecto's Inhaled IPF Therapy TD139 Shows Early Promise in Clinical Trial. Lung Disease News. Retrieved May 22, 2017.
  • Galecto. Galecto Biotech’s Lead Molecule TD139 Is Safe, Well Tolerated, with Direct Target Engagement and Biomarker Effects in a Clinical Phase Ib/IIa Trial in IPF Patients. Retrieved Mar 10, 2017.
  • MacKinnon, A. C., Gibbons, M. A., Farnworth, S. L., Leffler, H., Nilsson, U. J., Delaine, T., ... & Sethi, T. (2012). Regulation of transforming growth factor-β1–driven lung fibrosis by galectin-3. American journal of respiratory and critical care medicine, 185(5), 537-546.
  • Rajput, V. K., MacKinnon, A., Mandal, S., Collins, P., Blanchard, H., Leffler, H., ... & Nilsson, U. J. (2016). A Selective Galactose–Coumarin-Derived Galectin-3 Inhibitor Demonstrates Involvement of Galectin-3-glycan Interactions in a Pulmonary Fibrosis Model. Journal of medicinal chemistry, 59(17), 8141-8147.
  • Delaine, T., Collins, P., MacKinnon, A., Sharma, G., Stegmayr, J., Rajput, V. K., ... & Kahl‐Knutsson, B. (2016). Galectin‐3‐binding glycomimetics that strongly reduce bleomycin‐induced lung fibrosis and modulate intracellular glycan recognition. ChemBioChem, 17(18), 1759-1770.